Acute Coronary Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Coronary Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Acute coronary syndrome (ACS) encompasses ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina, constituting a subset of coronary heart disease (CHD) responsible for a third of deaths in individuals over 35. Unlike some asymptomatic forms of CHD, ACS is always symptomatic. Diagnosis begins with an ECG, crucial for distinguishing between STEMI, NSTEMI, and unstable angina. Initial ACS treatment involves aspirin (300 mg), heparin bolus, and intravenous (IV) heparin infusion, barring contraindications. Antiplatelet therapy with ticagrelor or clopidogrel is also advised, forming essential components of the comprehensive ACS management protocol.
The Acute Coronary Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Coronary Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Coronary Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Coronary Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Coronary Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Coronary Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
advanceCor GmbHAscendia Pharmaceuticals Inc
AstraZeneca Plc
Athera Biotechnologies AB
Beijing SH biotechnology Co Ltd
Bristol-Myers Squibb Co
Chengdu Shibeikang Biomedical Technology Co Ltd
CSL Ltd
DalCor Pharmaceuticals Inc
Diapin Therapeutics LLC
Han Wha Pharma Co Ltd
Hyloris Pharmaceuticals SA
LipimetiX Development Inc
Novartis AG
Orion Corp
Shanghai Pharmaceutical Group Co Ltd
Tianjin Institute of Pharmaceutical Research
Verseon Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Coronary Syndrome reports